Alliance Touts Imagent Synthetic Heart Imaging Agent As Easier To Store
This article was originally published in The Gray Sheet
Executive Summary
Alliance Pharmaceutical Corp. will launch its Imagent ultrasound heart imaging agent at the American Society of Echocardiography meeting in Orlando June 9-12
You may also be interested in...
Photogen Buys Alliance’s Imagent To Build Cardiovascular Imaging Franchise
Photogen Technologies' acquisition of Alliance Pharmaceutical's medical imaging assets provides a cardiovascular market entry at least three years ahead of the company's own internal R&D program
Photogen Buys Alliance’s Imagent To Build Cardiovascular Imaging Franchise
Photogen Technologies' acquisition of Alliance Pharmaceutical's medical imaging assets provides a cardiovascular market entry at least three years ahead of the company's own internal R&D program
Ultrasound contrast agents
Imavist contrast agent, developed jointly by Alliance Pharmaceutical and Schering AG, will enter a favorable reimbursement environment following FDA approval, the firms note. In July, CMS created new APCs defining ultrasound contrast agents as drugs and making them eligible for outpatient prospective "pass-through" payments covering 95% of their average wholesale cost, Alliance explains. The company has submitted the documentation requested by FDA in its August 2000 "approvable" letter and expects to launch the product by year-end